BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)

Reuters12-04

BRIEF-Heron <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Inclusion Of Aponvie (Aprepitant)

Dec 4 (Reuters) - Heron Therapeutics Inc HRTX.O:

HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)

Source text: ID:nGNX2zrgwS

Further company coverage: HRTX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588341882?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588341882","market":"nz","top_or_hot":-1,"title":"BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Inclusion Of Aponvie (Aprepitant)</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Heron Therapeutics Inc <span>HRTX.O</span>:</p><ul><li><p>HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)</p></li></ul><p>Source text: <span>ID:nGNX2zrgwS</span></p><p>Further company coverage: <span>HRTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-04 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Heron <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Inclusion Of Aponvie (Aprepitant)</title></head><body><p><span>Dec 4 (Reuters)</span><span> - </span>Heron Therapeutics Inc <span>HRTX.O</span>:</p><ul><li><p>HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)</p></li></ul><p>Source text: <span>ID:nGNX2zrgwS</span></p><p>Further company coverage: <span>HRTX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HRTX","symbol_name":"Heron Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA02P:1","article_id":"2588341882","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588341882","pubTimestamp":1764854236,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)Dec 4 (Reuters) - Heron Therapeutics Inc HRTX.O:HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE (APREPITANT) INJECTABLE EMULSION I","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HRTX":"Heron Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"简介-Heron Therapeutics宣布纳入Aponvie（阿瑞匹坦）","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HRTX":0.9},"content_text":"BRIEF-Heron Therapeutics Announces Inclusion Of Aponvie (Aprepitant)Dec 4 (Reuters) - Heron Therapeutics Inc HRTX.O:HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)Source text: ID:nGNX2zrgwSFurther company coverage: HRTX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588341882","isCrawlerRequest":true}